Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 4Head & Neck 1Gynecologic 1Gastrointestinal 1Endocrine 1CNS 1Breast 1

Conditions

Breast Neoplasms 9481Triple Negative Breast Neoplasms 635Neoplasms 413Lung Neoplasms 342Prostatic Neoplasms 321Ovarian Neoplasms 299Colorectal Neoplasms 289Neoplasm Metastasis 280Motor Activity 267Carcinoma, Intraductal, Noninfiltrating 231Colonic Neoplasms 193Breast Neoplasms, Male 172Lymphedema 170Melanoma 158Pancreatic Neoplasms 152Breast Carcinoma In Situ 151Carcinoma, Non-Small-Cell Lung 149Uterine Cervical Neoplasms 144Fatigue 140Head and Neck Neoplasms 132Pain 122Breast Cancer Female 122Brain Neoplasms 118Stomach Neoplasms 117Sarcoma 106Depression 105Breast Cancer Lymphedema 101Anxiety Disorders 101Lymphoma 96Cardiotoxicity 89

Interventions

fludarabine 1aldesleukin 1Nivolumab 1Ipilimumab 1Cyclophosphamide 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Giant Cell Tumor of Bone × Breast × Clear all
NCT03449108 2026-05-22

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
30 enrolled
BreastEndocrineGynecologicHead & NeckSarcoma

Bone Neoplasms, Ovarian Neoplasms, Sarcoma, Osteosarcoma, Giant Cell Tumor of Bone, Histiocytoma, Malignant Fibrous, Triple Negative Breast Neoplasms, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡